company background image
ENSC

Ensysce Biosciences NasdaqCM:ENSC Stock Report

Last Price

US$1.04

Market Cap

US$3.1m

7D

-64.1%

1Y

-98.3%

Updated

07 Dec, 2022

Data

Company Financials +
ENSC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

ENSC Stock Overview

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States.

Ensysce Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ensysce Biosciences
Historical stock prices
Current Share PriceUS$1.04
52 Week HighUS$140.00
52 Week LowUS$1.00
Beta0.28
1 Month Change-56.30%
3 Month Change-84.30%
1 Year Change-98.26%
3 Year Change-99.50%
5 Year Changen/a
Change since IPO-99.46%

Recent News & Updates

Recent updates

Shareholder Returns

ENSCUS BiotechsUS Market
7D-64.1%-0.3%-3.7%
1Y-98.3%-11.2%-21.2%

Return vs Industry: ENSC underperformed the US Biotechs industry which returned -11.2% over the past year.

Return vs Market: ENSC underperformed the US Market which returned -20.6% over the past year.

Price Volatility

Is ENSC's price volatile compared to industry and market?
ENSC volatility
ENSC Average Weekly Movement22.9%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: ENSC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: ENSC's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a6D. Kirkpatrickhttps://www.ensysce.com

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.

Ensysce Biosciences, Inc. Fundamentals Summary

How do Ensysce Biosciences's earnings and revenue compare to its market cap?
ENSC fundamental statistics
Market CapUS$3.07m
Earnings (TTM)-US$30.40m
Revenue (TTM)US$2.73m

1.1x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENSC income statement (TTM)
RevenueUS$2.73m
Cost of RevenueUS$15.58m
Gross Profit-US$12.86m
Other ExpensesUS$17.55m
Earnings-US$30.40m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-10.31
Gross Margin-471.76%
Net Profit Margin-1,115.64%
Debt/Equity Ratio-139.2%

How did ENSC perform over the long term?

See historical performance and comparison